FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.
The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.
In the reports customers will find basic market information on the products and the following takeaways:
- Leading and emerging trends;
- Medical enterprises;
- Critical analysis for best strategies;
- Multichannel marketing modelling to guide the customers to the right channels and content;
- Key success factors and opportunities for pharma industry;
- Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.
Publications found:
700
Sort by:
REMS: A Standardized Approach to Risk Management
US$ 395.00
Risk Evaluation and Mitigation Strategies. Until recently, the Federal Drug Administration’s REMS program impacted drugs that would not have been otherwise approved due to their risks. The hurdles, co...
September 2010
42 pages
Pharmaceutical Market Access in Latin America
US$ 395.00
With its top eight markets valued at more than $30 billion in 2009, Latin America represents shining hope for an industry in flux. Strong, steady growth, resiliency in the face of global downturn, pos...
August 2010
58 pages
Pay-for-Delay: An Unsettled Future Lies Ahead
US$ 395.00
Anti-competitive or just good business?That’s the question facing the pharmaceutical industry and regulators alike, as companies dealing with drugs going off-patent increasingly rely on pay-for-delay...
July 2010
36 pages
Specialty Generics: Climbing the Value Chain
US$ 195.00
“Mighty things from small beginnings grow,” John Dryden once astutely noted. Although the influential 17th century poet and literary critic knew nothing of medicine and marketing, his words ring true...
June 2010
34 pages
Branded Generics: A Gateway to Emerging Markets
US$ 295.00
Around the globe, emerging markets are on the move. From Brazil, Russia and India to China, Turkey, Mexico and South Korea, experts predict emerging markets will represent 70 percent of industry growt...
June 2010
46 pages
Pharma Sales Forces: Mexico
US$ 295.00
Enchiladas, cerveza, sombreros and ponchos: Forget what you thought you knew about Mexico. With the 11th largest economy in the world and a pharmaceutical industry expected to hit $14.9 billion by 201...
June 2010
45 pages
Trends in Mobile Medicine: Smartphone Apps for Physicians
US$ 395.00
“Healing is a matter of time,” Hippocrates once said, “but it is sometimes also a matter of opportunity.”As smartphone technology rapidly evolves and puts knowledge literally into the hands of physici...
May 2010
66 pages
Pharma 2.0 -- De-Risking the Business Model
US$ 395.00
Adapt. Evolve. Survive. Darwinian Theory as a business model for the pharmaceutical industry? Never has it been more apt—or timely. As it enters one of its most challenging periods ever, the pharmaceu...
May 2010
44 pages
The State of Merck & Co
US$ 295.00
New directions. New faces. Major new facilities. As 2009 ended and the curtain lifted on 2010, Merck & Co emerged from its $41.1 billion union with Schering-Plough with a whole new outlook. Starti...
April 2010
38 pages
The State of Roche
US$ 295.00
Expect the unexpected. For pharma giant Roche, those were words to live by as 2009 came to a close. Despite a strong showing in news analysis — of 179 articles published internationally on the compan...
April 2010
39 pages
The Life Cycle of Drug Brands: Concept to Market Share
US$ 395.00
The Life Cycle of Drug Brands: Concept to Market ShareThe match is on. The goal is in sight. Yet the rules of the game are shifting. For the $60 billion pharmaceutical marketing industry, keeping up w...
April 2010
55 pages
Leading Thoughts on Pharma & Social Media
US$ 295.00
Out of 430 million Facebook users, 60 million Twitter accounts and countless blogs, the cacophony of voices and opinions on the Internet is relentless. But that doesn’t mean the pharmaceutical industr...
March 2010
75 pages
The AstraZeneca Intelligence Dossier
US$ 295.00
One step forward, two steps back. At least that’s what the last two quarters of 2009 seemed like for pharmaceutical giant, AstraZeneca. Despite a strong showing in news analysis — of 221 articles publ...
March 2010
69 pages
The Johnson & Johnson Intelligence Dossier
US$ 295.00
May you live in interesting times—or so the old curse goes. Johnson & Johnson is certainly doing just that. After a year of upsets and some victories, J&J ended the last half of 2009 with the...
March 2010
35 pages
The Bristol-Myers Squibb Intelligence Dossier
US$ 295.00
“Without the strength to endure the crisis, one will not see the opportunity within,” author and business commentator Chin-Ning Chu recently said. “It is within the process of endurance that opportuni...
March 2010
51 pages
The Eli Lilly Intelligence Dossier
US$ 295.00
From the ashes of recent economic fires, a new leader is rising. Following one of the worst years ever for the pharmaceutical industry, in which economic downturn was compounded by regulatory crises,...
March 2010
46 pages
Engaging with Physicians in an Era of Transparency
US$ 595.00
“It's no use going back to yesterday,” Alice said in Wonderland, “because I was a different person then.”As Alice’s environment changed her, so, too, is an era of “looking glass” transparency changing...
March 2010
51 pages
Branded vs Generics Drugs in Latin America
US$ 395.00
On every border, across every frontier of Latin America, a revolution is underway. Prefaced by the ground-breaking Hatch-Waxman Act of 1984, the war for market share between generic and branded pharma...
February 2010
52 pages
KOL Management - The New Rules
US$ 395.00
“When the going gets tough,” Joseph P. Kennedy once said, “the tough get going…” And when it comes to the beleaguered pharmaceutical industry, he could have added, “… then they rethink how they do bus...
January 2010
33 pages
The CME Landscape - Change and Challenges
US$ 395.00
“The future influences the present just as much as the past.” ~ (Friedrich Nietzsche, scholar and philosopher)When it comes to the past, present and future of the continuing medical education (CME) in...
January 2010
36 pages
Pharma & Social Media -- Report Collection
US$ 975.00
1.7 billion users
More than 380 per cent growth since 2000
Nearly 75 per cent penetration in North America alone1
The fastest growing, most complex, yet easiest-to-access...
November 2009
161 pages
The Roche Intelligence Dossier
US$ 295.00
As the fourth largest pharmaceutical company in the world, with annual revenues of $43.9 billion, some of the most instantly recognisable drugs marketed and the kind of pipeline smaller companies only...
November 2009
48 pages
The GSK Intelligence Dossier
US$ 295.00
After two anemic years, GSK is ready to breathe new life.Despite intense competition from generics in the US, the company has finally reported a healthy growth in the third quarter of 2009.Now, eager...
November 2009
53 pages
The Novartis Intelligence Dossier
US$ 295.00
International censure over Novartis’ grave delays in supplying the H1N1 vaccine.Renewed criticism by an institutional investor for CEO Daniel Vasella’s substantial pay package and considerable power.A...
November 2009
55 pages
The Value of a Good Reputation in Pharma
US$ 795.00
“It takes many good deeds to build a good reputation,” Benjamin Franklin once wisely observed, “and only one bad one to lose it.”How many good deeds will it take to repair the pharmaceutical industry’...
November 2009
40 pages
Conference Intelligence Dossier: EASD Annual Meeting 2009
US$ 995.00
The numbers are staggering: More than 200 million people around the world now suffer from diabetes and its major complications. According to the World Health Organization, that figure is expected to s...
October 2009
90 pages
The Pfizer Intelligence Dossier
US$ 295.00
In boardrooms, around water coolers and behind closed office doors, decision-makers in the pharmaceutical industry are asking questions: What’s happening with Pfizer? What developments have occurred i...
October 2009
60 pages
Pharma Sales Forces: Change in the Face of Adversity
US$ 395.00
“Change,” futurist Alvin Toffler once said, “is the process by which the future invades our lives.” For the pharmaceutical sales industry, that future is unfolding now. Dropping revenue, increasingly...
October 2009
40 pages
Pharma and Social Media -- the Leaders and Followers
US$ 295.00
The phenomenon of social media is seeing the creation of information and interest communities on an unparalled scale, and health is among the most popular.For pharmaceutical companies, the potential b...
August 2009
75 pages
Roche & Genentech: a Model for Future Biotech Deals?
US$ 295.00
Could this single deal mark a phase of big pharma/biotech consolidation? In March 2009, after months of negotiations, Roche acquired the 44 percent of shares that it did not already own in its long-t...
August 2009
42 pages
BMS & Medarex: a Valuable Partnership?
US$ 295.00
A positive move, but not one which deals with Bristol-Myers Squibb’s upcoming patent expiry problems On July 22, 2009, Bristol-Myers Squibb announced that it would acquire – at a considerable premium...
August 2009
ASCO 2009: Significant Developments in Context
US$ 995.00
The recent ASCO meeting was attended by around 30,000 cancer researchers and physicians and over 4,000 abstracts covering a wide range of clinical trial results and related topics were presented. How...
July 2009
175 pages
Johnson & Johnson: Positioning for Market Leadership?
US$ 295.00
How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? For competitors and investors alike this is a key question, and one that must be considered in the light of t...
July 2009
Branded Generics: Strategies and Tactics for Winning in Latin America
US$ 1,995.00
... …but in Mexico it’s the small companies that have done well in generics.” Xavier Tello, Independent healthcare industry expert “As a manufacturer, you should ... in hospital-driven niches, such as oncology Branded Generics: Strategies and Tactics for Winning in Latin America answers key questions: Who are ...
March 2009
71 pages